

This spreadsheet is updated monthly and enables self-audit of a medicines formulary for adherence to current NICE Technology Appraisals. All guidelines refer to adults unless indicated.

ICB commissioned 26  
Non-ICB commissioned 47  
Not applicable 30  
ICB commissioned and approved 22 (85%)  
Average days to compliance 75

Title	Recommendation	Published	Type	Implement	Commissioner	ICB decision	Compliance	Notes	Local information
<a href="#">Pegylated liposomal irinotecan in combination for untreated metastatic pancreatic cancer (terminated appraisal) [TA1052]</a>	Terminated appraisal	02/04/2025	TA					N/A	Terminated appraisal
<a href="#">Efanesoctocog alfa for treating and preventing bleeding episodes in haemophilia A in people 2 years and over [TA1051]</a>	Recommended	02/04/2025	TA		Non-ICB			This technology is commissioned by NHS England. Providers are NHS hospital trusts.	NHS England
<a href="#">Ruxolitinib for treating acute graft versus host disease that responds inadequately to corticosteroids in people 12 years and over [TA1054]</a>	Recommended	15/04/2025	TA		Non-ICB			This technology is commissioned by NHS England. Providers are NHS hospital trusts / tertiary providers.	NHS England
<a href="#">Cladribine for treating active relapsing forms of multiple sclerosis [TA1053]</a>	Recommended	15/04/2025	TA		Non-ICB			This technology is commissioned by NHS England. Providers are NHS hospital trusts	NHS England
<a href="#">Relugolix–estradiol–norethisterone for treating symptoms of endometriosis [TA1057]</a>	Recommended	16/04/2025	TA	15/07/2025	ICB	19/06/2025	64	This technology is commissioned by integrated care boards. Providers are Primary care and NHS hospital trusts.	Amber initiated RAG rating
<a href="#">Molnupiravir for treating COVID-19 [TA1056]</a>	Recommended	16/04/2025	TA	15/07/2025	ICB	19/06/2025	64	This technology is commissioned by integrated care boards. Providers are Primary care providers and NHS hospital trusts.	Red RAG rating
<a href="#">Rucaparib for maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy [TA1055]</a>	Recommended	16/04/2025	TA		Non-ICB			This technology is commissioned by NHS England. Providers are NHS hospital trusts	NHS England
<a href="#">Tislelizumab in combination for untreated advanced non-small-cell lung cancer (terminated appraisal) [TA1058]</a>	Terminated appraisal	23/04/2025	TA					N/A	Terminated appraisal
<a href="#">Nirmatrelvir plus ritonavir, sotrovimab and tocilizumab for treating COVID-19 [TA878]</a>	Recommended	01/05/2025	TA (Update)		ICB			This technology is commissioned by integrated care boards. Providers are NHS Hospital trusts and primary care. Statement amended.	Red RAG rating
<a href="#">Cenobamate for treating focal onset seizures in epilepsy [TA753]</a>	Recommended	06/05/2025	TA (Update)		ICB			TA update: The wording in recommendation 1.1 has been updated to address concerns raised by the clinical community that restricting starting treatment in a tertiary care setting has resulted in inequitable access to the treatment. Update addressed in statement review.	Amber initiated RAG rating
<a href="#">Omaveloxolone for treating Friedreich's ataxia in people 16 years and over (terminated appraisal)</a>	Terminated appraisal	06/05/2025	TA					N/A	Terminated appraisal
<a href="#">Brentuximab vedotin in combination for untreated stage 3 or 4 CD30-positive Hodgkin lymphoma [TA1059]</a>	Recommended	07/05/2025	TA		Non-ICB			This technology is commissioned by NHS England. Providers are NHS hospital trusts	NHS England
<a href="#">Osimertinib with pemetrexed and platinum-based chemotherapy for untreated EGFR mutation-positive advanced non-small-cell lung cancer [TA1060]</a>	Recommended	08/05/2025	TA		Non-ICB			This technology is commissioned by NHS England. Providers are NHS hospital trusts	NHS England
<a href="#">Erdafitinib for treating unresectable or metastatic urothelial cancer with FGFR3 alterations after a PD-1 or PD-L1 inhibitor [TA1062]</a>	Recommended	12/05/2025	TA		Non-ICB			This technology is commissioned by NHS England. Providers are NHS hospital trusts	NHS England

Title	Recommendation	Published	Type	Implement	Commissioner	ICB decision	Compliance	Notes	Local information
<a href="#">Capiivasertib with fulvestrant for treating hormone receptor-positive HER2-negative advanced breast cancer after endocrine treatment [TA1063]</a>	Recommended	15/05/2025	TA		Non-ICB			This technology is commissioned by NHS England. Providers are NHS hospital trusts	NHS England
<a href="#">Dostarlimab with platinum-based chemotherapy for treating primary advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency [TA1064]</a>	Recommended	22/05/2025	TA		Non-ICB			This technology is commissioned by NHS England. Providers are NHS hospital trusts	NHS England
<a href="#">Nivolumab plus ipilimumab for untreated unresectable or metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency [TA1065]</a>	Recommended	28/05/2025	TA		Non-ICB			This technology is commissioned by NHS England. Providers are NHS hospital trusts	NHS England
<a href="#">Tislelizumab for treating unresectable advanced oesophageal squamous cell cancer after platinum-based chemotherapy (terminated appraisal) [TA1068]</a>	Terminated appraisal	29/05/2025	TA					N/A	Terminated appraisal
<a href="#">Somapacitan for treating growth hormone deficiency in people 3 to 17 years [TA1066]</a>	Recommended	03/06/2025	TA (Cost comparison)	03/07/2025	ICB	17/07/2025	44	This technology is commissioned by integrated care boards. Providers are NHS hospital trusts.	Red RAG rating
<a href="#">Efgartiqimod for treating antibody-positive generalised myasthenia gravis [TA1069]</a>	Not recommended	04/06/2025	TA					N/A	Not recommended
<a href="#">Linzagolix for treating symptoms of endometriosis [TA1067]</a>	Recommended	04/06/2025	TA	02/09/2025	ICB	28/08/2025	85	This technology is commissioned by integrated care boards. Providers are NHS Hospital trusts and primary care.	Amber retained RAG rating
<a href="#">Spesolimab for treating generalised pustular psoriasis flares [TA1070]</a>	Recommended	18/06/2025	TA	16/09/2025	ICB	27/08/2025	70	This technology is commissioned by integrated care boards. Providers are NHS hospital trusts - acute and Tertiary care	Red RAG rating
<a href="#">Tislelizumab for treating advanced non-small-cell lung cancer after platinum-based chemotherapy (terminated appraisal) [TA1072]</a>	Terminated appraisal	19/06/2025	TA					N/A	Terminated appraisal
<a href="#">Atezolizumab for adjuvant treatment of resected non-small-cell lung cancer [TA1071]</a>	Recommended	19/06/2025	TA		Non-ICB			This technology is commissioned by NHS England. Providers are NHS hospital trusts	NHS England
<a href="#">Marstacimab for treating severe haemophilia A or B in people 12 years and over without anti-factor antibodies [TA1073]</a>	Partially recommended	24/06/2025	TA		Non-ICB			This technology is commissioned by NHS England. Providers are NHS hospital trusts	NHS England
<a href="#">Sparsentan for treating primary IgA nephropathy [TA1074]</a>	Recommended	25/06/2025	TA	23/09/2025	ICB	27/08/2025	63	This technology is commissioned by integrated care boards. Providers are NHS hospital trusts.	Red RAG rating
<a href="#">Fosdenopterin for treating molybdenum cofactor deficiency type A (terminated appraisal) [TA1078]</a>	Terminated appraisal	25/06/2025	TA					N/A	Terminated appraisal
<a href="#">Nemolizumab for treating moderate to severe atopic dermatitis in people 12 years and over [TA1077]</a>	Recommended	02/07/2025	TA	30/09/2025	ICB	27/08/2025	56	This technology is commissioned by NHS England for use in adolescents and integrated care boards for use in adults. Providers are NHS hospital trusts.	Red RAG rating
<a href="#">Adagrasib for previously treated KRAS G12C mutation-positive advanced non-small-cell lung cancer (terminated appraisal) [TA1076]</a>	Terminated appraisal	02/07/2025	TA					N/A	Terminated appraisal
<a href="#">Dapaqlifozin for treating chronic kidney disease [TA1075]</a>	Recommended	02/07/2025	TA (Cost comparison)	01/08/2025	ICB	21/08/2025	50	This technology is commissioned by integrated care boards. Providers are NHS hospital trusts and primary care providers.	Green RAG rating
<a href="#">Mirikizumab for previously treated moderately to severely active Crohn's disease [TA1080]</a>	Recommended	10/07/2025	TA (Cost comparison)	09/08/2025	ICB	21/08/2025	42	This technology is commissioned by integrated care boards. Providers are NHS hospital trusts.	Red RAG rating

Title	Recommendation	Published	Type	Implement	Commissioner	ICB decision	Compliance	Notes	Local information
<a href="#">Zanubrutinib for treating relapsed or refractory mantle cell lymphoma [TA1081]</a>	Recommended	10/07/2025	TA		Non-ICB			This technology is commissioned by NHS England. Providers are NHS hospital trusts	NHS England
<a href="#">Letermovir for preventing cytomegalovirus infection after a kidney transplant (terminated appraisal) [TA1082]</a>	Terminated appraisal	23/07/2025	TA					N/A	Terminated appraisal
<a href="#">Fruquintinib for previously treated metastatic colorectal cancer [TA1079]</a>	Recommended	23/07/2025	TA		Non-ICB			This technology is commissioned by NHS England. Providers are NHS hospital trusts	NHS England
<a href="#">Lisocabtagene maraleucel for treating relapsed or refractory aggressive B-cell non-Hodgkin lymphoma after 1 systemic treatment when a stem cell transplant is unsuitable (terminated appraisal) [TA1083]</a>	Terminated appraisal	23/07/2025	TA					N/A	Terminated appraisal
<a href="#">Letermovir for preventing cytomegalovirus infection after a kidney transplant (terminated appraisal) [TA1082]</a>	Terminated appraisal	23/07/2025	TA					N/A	Terminated appraisal
<a href="#">Cenobamate for treating focal onset seizures in epilepsy [TA753]</a>	Recommended	24/07/2025	TA (Update)		ICB			TA update. The 'why the committee made these recommendations' section has been amended to reflect the updated recommendations. No action required.	Amber initiated RAG rating
<a href="#">Vanzacaftor-tezacaftor-deutivacaftor for treating cystic fibrosis with 1 or more F508del mutations in the CFTR gene in people 6 years and over [TA1085]</a>	Recommended	30/07/2025	TA		Non-ICB			This technology is commissioned by NHS England. Providers are NHS hospital trusts	NHS England
<a href="#">Betula verrucosa for treating moderate to severe allergic rhinitis or conjunctivitis caused by tree pollen [TA1087]</a>	Recommended	06/08/2025	TA	04/11/2025	ICB	22/12/2025	138	This technology is commissioned by integrated care boards. Providers are Primary care and NHS hospital trusts.	Amber retained RAG rating
<a href="#">Ribociclib with an aromatase inhibitor for adjuvant treatment of hormone receptor-positive HER2-negative early breast cancer at high risk of recurrence [TA1086]</a>	Recommended	06/08/2025	TA		Non-ICB			This technology is commissioned by NHS England. Providers are NHS hospital trusts	NHS England
<a href="#">Sacituzumab govitecan for treating hormone receptor-positive HER2-negative metastatic breast cancer after 2 or more treatments (terminated appraisal) [TA1089]</a>	Terminated appraisal	13/08/2025	TA					N/A	Terminated appraisal
<a href="#">Ruxolitinib cream for treating non-segmental vitiligo in people 12 years and over [TA1088]</a>	Not recommended	13/08/2025	TA					Not recommended. ICB-commissioned.	DNP RAG rating
<a href="#">Durvalumab with tremelimumab for untreated advanced or unresectable hepatocellular carcinoma [TA1090]</a>	Recommended	19/08/2025	TA		Non-ICB			This technology is commissioned by NHS England. Providers are NHS hospital trusts	NHS England
<a href="#">Tarlatab for extensive-stage small-cell lung cancer after 2 or more treatments [TA1091]</a>	Not recommended	20/08/2025	TA					Not recommended. NHSE-commissioned.	NHS England
<a href="#">Pembrolizumab with carboplatin and paclitaxel for untreated primary advanced or recurrent endometrial cancer [TA1092]</a>	Recommended	27/08/2025	TA		Non-ICB			This technology is commissioned by NHS England. Providers are NHS hospital trusts	NHS England
<a href="#">Guselkumab for previously treated moderately to severely active Crohn's disease [TA1095]</a>	Recommended	28/08/2025	TA	26/11/2025	ICB	19/11/2025	83	This technology is commissioned by integrated care boards. Providers are NHS hospital trusts.	Red RAG rating
<a href="#">Guselkumab for treating moderately to severely active ulcerative colitis [TA1094]</a>	Recommended	28/08/2025	TA	26/11/2025	ICB	19/11/2025	83	This technology is commissioned by integrated care boards. Providers are NHS hospital trusts.	Red RAG rating

Title	Recommendation	Published	Type	Implement	Commissioner	ICB decision	Compliance	Notes	Local information
<a href="#">Idebenone for treating visual impairment in Leber's hereditary optic neuropathy in people 12 years and over [TA1093]</a>	Recommended	28/08/2025	TA		Non-ICB			This technology is commissioned by NHS England. Providers are NHS hospital trusts	NHS England
<a href="#">Tirzepatide for treating type 2 diabetes [TA924]</a>	Recommended	01/09/2025	TA (Update)		ICB			TA update. Commercial arrangement added to the recommendation. Prices and details of the commercial arrangement also added to the information on tirzepatide section. Statement updated.	Green RAG rating
<a href="#">Tirzepatide for managing overweight and obesity [TA1026]</a>	Recommended	01/09/2025	TA (Update)		ICB			TA update. Commercial arrangement added to the recommendation. Prices and details of the commercial arrangement also added to the information on tirzepatide section. Statement updated.	Green RAG rating
<a href="#">Benralizumab for treating relapsing or refractory eosinophilic granulomatosis with polyangiitis [TA1096]</a>	Recommended	03/09/2025	TA		Non-ICB			This technology is commissioned by NHS England. Providers are NHS hospital trusts	NHS England
<a href="#">Enfortumab vedotin with pembrolizumab for untreated unresectable or metastatic urothelial cancer when platinum-based chemotherapy is suitable [TA1097]</a>	Recommended	11/09/2025	TA		Non-ICB			This technology is commissioned by NHS England. Providers are NHS hospital trusts	NHS England
<a href="#">Isatuximab in combination for untreated multiple myeloma when a stem cell transplant is unsuitable [TA1098]</a>	Recommended	24/09/2025	TA		Non-ICB			This technology is commissioned by NHS England. Providers are NHS hospital trusts	NHS England
<a href="#">Mirabegron for treating neurogenic detrusor overactivity in people 3 to 17 years (terminated appraisal) [TA1100]</a>	Terminated appraisal	01/10/2025	TA					N/A	Terminated appraisal
<a href="#">Durvalumab for treating limited-stage small-cell lung cancer after platinum-based chemoradiotherapy [TA1099]</a>	Recommended	01/10/2025	TA		Non-ICB			This technology is commissioned by NHS England. Providers are NHS hospital trusts	NHS England
<a href="#">Garadacimab for preventing recurrent attacks of hereditary angioedema in people 12 years and over [TA1101]</a>	Recommended	08/10/2025	TA		Non-ICB			This technology is commissioned by NHS England. Providers are NHS hospital trusts	NHS England
<a href="#">Targeted-release budesonide for treating primary IgA nephropathy [TA937]</a>	Recommended	09/10/2025	TA (Update)		ICB			TA update. NICE updated recommendation 1.1 to change the unit for urine protein-to-creatinine ratio (UPCR) to mg/mmol from g/g. A UPCR of 170 mg/mmol or more equates to the 1.5 g/g or more measurement specified in the marketing authorisation indication for targeted-release budesonide. No action required.	Red RAG rating
<a href="#">Sparsentan for treating primary IgA nephropathy [TA1074]</a>	Recommended	09/10/2025	TA (Update)		ICB			TA update. NICE updated recommendations 1.1 and 1.2 to change the unit for urine protein-to-creatinine ratio (UPCR) to mg/mmol from g/g. A UPCR of 85 mg/mmol or more equates to the 0.75 g/g or more measurement specified in the marketing authorisation indication for sparsentan. A UPCR of 199 mg/mmol or more equates to 1.76 g/g or more. No action required.	Red RAG rating
<a href="#">Lorlatinib for ALK-positive advanced non-small-cell lung cancer that has not been treated with an ALK inhibitor [TA1103]</a>	Recommended	21/10/2025	TA		Non-ICB			This technology is commissioned by NHS England. Providers are NHS hospital trusts	NHS England
<a href="#">Sarilumab for treating polyarticular or oligoarticular juvenile idiopathic arthritis in people 2 to 17 years (terminated appraisal) [TA1104]</a>	Terminated appraisal	22/10/2025	TA					N/A	Terminated appraisal

Title	Recommendation	Published	Type	Implement	Commissioner	ICB decision	Compliance	Notes	Local information
<a href="#">Clascoterone for treating acne vulgaris in people 12 years and over (terminated appraisal) [TA1105]</a>	Terminated appraisal	22/10/2025	TA					N/A	Terminated appraisal
<a href="#">Iptacopan for treating complement 3 glomerulopathy (terminated appraisal) [TA1102]</a>	Terminated appraisal	23/10/2025	TA					N/A	Terminated appraisal
<a href="#">Delgocitinib for treating moderate to severe chronic hand eczema [TA1107]</a>	Recommended	05/11/2025	TA	03/02/2026	ICB	19/03/2026	134	This technology is commissioned by integrated care boards. Providers are NHS hospital trusts.	Red RAG rating
<a href="#">Cabotegravir for preventing HIV-1 in adults and young people [TA1106]</a>	Partially recommended	05/11/2025	TA		Non-ICB			This technology is commissioned by NHS England. Providers are Sexual health service providers.	NHS England
<a href="#">Cemiplimab with platinum-based chemotherapy for untreated advanced non-small-cell lung cancer [TA1108]</a>	Not recommended	05/11/2025	TA					N/A	Not recommended
<a href="#">Darolutamide with androgen deprivation therapy for treating hormone-sensitive metastatic prostate cancer [TA1109]</a>	Recommended	12/11/2025	TA		Non-ICB			This technology is commissioned by NHS England. Providers are NHS hospital trusts	NHS England
<a href="#">Trastuzumab deruxtecan for treating hormone receptor-positive HER2-low metastatic breast cancer after 2 or more endocrine treatments (terminated appraisal) [TA1112]</a>	Terminated appraisal	19/11/2025	TA					N/A	Terminated appraisal
<a href="#">Nintedanib for treating fibrosing interstitial lung disease in people 6 to 17 years (terminated appraisal) [TA1111]</a>	Terminated appraisal	19/11/2025	TA					N/A	Terminated appraisal
<a href="#">Abiraterone (originator and generics) for treating newly diagnosed high-risk hormone-sensitive metastatic prostate cancer [TA1110]</a>	Recommended	19/11/2025	TA		Non-ICB			This technology is commissioned by NHS England. Providers are NHS hospital trusts	NHS England
<a href="#">Talquetamab for treating relapsed and refractory multiple myeloma after 3 or more treatments [TA1114]</a>	Recommended	03/12/2025	TA		Non-ICB			This technology is commissioned by NHS England. Providers are NHS hospital trusts	NHS England
<a href="#">Glofitamab with gemcitabine and oxaliplatin for treating relapsed or refractory diffuse large B-cell lymphoma [TA1113]</a>	Recommended	03/12/2025	TA		Non-ICB			This technology is commissioned by NHS England. Providers are NHS hospital trusts	NHS England
<a href="#">Vutrisiran for treating transthyretin amyloidosis with cardiomyopathy [TA1115]</a>	Recommended	10/12/2025	TA		Non-ICB			This technology is commissioned by NHS England. Providers are NHS hospital trusts	NHS England
<a href="#">Obecabtagene autoleucel for treating relapsed or refractory B-cell precursor acute lymphoblastic leukaemia [TA1116]</a>	Recommended	11/12/2025	TA		Non-ICB			This technology is commissioned by NHS England. Providers are NHS hospital trusts	NHS England
<a href="#">Dostarlimab with platinum-containing chemotherapy for treating primary advanced or recurrent endometrial cancer with microsatellite stability or mismatch repair proficiency [TA1117]</a>	Recommended	16/12/2025	TA		Non-ICB			This technology is commissioned by NHS England. Providers are NHS hospital trusts	NHS England
<a href="#">Venetoclax with obinutuzumab for untreated chronic lymphocytic leukaemia [TA1119]</a>	Recommended	07/01/2026	TA		Non-ICB			This technology is commissioned by NHS England. Providers are NHS hospital trusts	NHS England

Title	Recommendation	Published	Type	Implement	Commissioner	ICB decision	Compliance	Notes	Local information
<a href="#">Entrectinib for treating NTRK fusion-positive solid tumours in people 12 years and over (terminated appraisal) [TA1118]</a>	Terminated appraisal	07/01/2026						N/A	Terminated appraisal
<a href="#">Avelumab with axitinib for untreated advanced renal cell carcinoma [TA1120]</a>	Recommended	08/01/2026			Non-ICB			This technology is commissioned by NHS England. Providers are NHS hospital trusts	NHS England
<a href="#">Acoramidis for treating transthyretin amyloidosis with cardiomyopathy [TA1121]</a>	Recommended	14/01/2026			Non-ICB			This technology is commissioned by NHS England. Providers are NHS hospital trusts	NHS England
<a href="#">Amivantamab with lazertinib for untreated EGFR mutation-positive advanced non-small-cell lung cancer [TA1122]</a>	Recommended	21/01/2026			Non-ICB			This technology is commissioned by NHS England. Providers are NHS hospital trusts	NHS England
<a href="#">Depemokimab for treating chronic rhinosinusitis with nasal polyps in adults (terminated appraisal) [TA1123]</a>	Terminated appraisal	22/01/2026						N/A	Terminated appraisal
<a href="#">Sirolimus for treating facial angiofibroma caused by tuberous sclerosis complex in people 6 years and over (terminated appraisal) [TA972]</a>	Terminated appraisal	27/01/2026						N/A	Terminated appraisal
<a href="#">Pembrolizumab with pemetrexed and platinum-based chemotherapy for untreated unresectable advanced malignant pleural mesothelioma (terminated appraisal) [TA1125]</a>	Terminated appraisal	27/01/2026						N/A	Terminated appraisal
<a href="#">Concizumab for treating haemophilia A or B in people 12 years and over with factor inhibitors (terminated appraisal) [TA1124]</a>	Terminated appraisal	27/01/2026						N/A	Terminated appraisal
<a href="#">Natalizumab (originator and biosimilar) for treating highly active relapsing–remitting multiple sclerosis after disease-modifying therapy [TA1126]</a>	Partially recommended	28/01/2026			Non-ICB			This technology is commissioned by NHS England. Providers are NHS hospital trusts	NHS England
<a href="#">Targeted-release budesonide for treating primary IgA nephropathy [TA1128]</a>	Recommended	04/02/2026	TA	05/05/2026	ICB			This technology is commissioned by integrated care boards. Providers are NHS hospital trusts.	Red RAG proposed
<a href="#">Nivolumab with chemotherapy for neoadjuvant treatment then alone for adjuvant treatment of resectable non-small-cell lung cancer [TA1127]</a>	Recommended	04/02/2026	TA		Non-ICB			This technology is commissioned by NHS England. Providers are NHS hospital trusts	NHS England
<a href="#">Talazoparib with enzalutamide for untreated hormone-relapsed metastatic prostate cancer [TA1130]</a>	Recommended	11/02/2026	TA		Non-ICB			This technology is commissioned by NHS England. Providers are NHS hospital trusts	NHS England
<a href="#">Obinutuzumab with mycophenolate mofetil for treating lupus nephritis [TA1131]</a>	Recommended	12/02/2026	TA		Non-ICB			This technology is commissioned by NHS England. Providers are NHS hospital trusts	NHS England
<a href="#">Niraparib for maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy [TA1129]</a>	Recommended	12/02/2026	TA		Non-ICB			This technology is commissioned by NHS England. Providers are NHS hospital trusts	NHS England
<a href="#">Ruxolitinib for treating moderate to severe chronic graft versus host disease after an allogeneic stem cell transplant in people 28 days to 17 years (terminated appraisal) [TA1132]</a>	Terminated appraisal	17/02/2026	TA					N/A	Terminated appraisal

Title	Recommendation	Published	Type	Implement	Commissioner	ICB decision	Compliance	Notes	Local information
<a href="#">Dupilumab for treating severe chronic rhinosinusitis with nasal polyps [TA1134]</a>	Recommended	18/02/2026	TA		Non-ICB			This technology is commissioned by NHS England. Providers are NHS hospital trusts	NHS England
<a href="#">Belantamab mafodotin with pomalidomide and dexamethasone for previously treated multiple myeloma [TA1133]</a>	Recommended	18/02/2026	TA		Non-ICB			This technology is commissioned by NHS England. Providers are NHS hospital trusts	NHS England
<a href="#">Baloxavir marboxil for treating and preventing influenza in children 1 to 11 years (terminated appraisal) [TA1135]</a>	Terminated appraisal	19/02/2026	TA					N/A	Terminated appraisal
<a href="#">Canagliflozin for treating type 2 diabetes in people 10 to 17 years (terminated appraisal) [TA1137]</a>	Terminated appraisal	25/02/2026	TA					N/A	Terminated appraisal
<a href="#">Bevacizumab (originator and biosimilars) with fluoropyrimidine-based chemotherapy for metastatic colorectal cancer [TA1136]</a>	Recommended	25/02/2026	TA		Non-ICB			This technology is commissioned by NHS England. Providers are NHS hospital trusts	NHS England
<a href="#">Nirmatrelvir plus ritonavir and tocilizumab for treating COVID-19 [TA878]</a>	Recommended	26/02/2026	TA (Update)		ICB			TA update: NICE removed the recommendation on sotrovimab because the company has discontinued manufacturing, supply, distribution and marketing in the UK. NICE also included information in section 1 explaining why the recommendation on casirivimab plus imdevimab was removed in March 2024.	Red RAG rating
<a href="#">Molnupiravir for treating COVID-19 [TA1056]</a>	Recommended	26/02/2026	TA (Update)		ICB			TA update: NICE removed sotrovimab from recommendation 1.1 because the company has discontinued manufacturing, supply, distribution and marketing in the UK.	Red RAG rating
<a href="#">Durvalumab with gemcitabine and cisplatin for neoadjuvant treatment then alone for adjuvant treatment of muscle-invasive bladder cancer [TA1138]</a>	Recommended	02/03/2026	TA		Non-ICB			This technology is commissioned by NHS England. Providers are NHS hospital trusts	NHS England
<a href="#">Epcoritamab for treating relapsed or refractory follicular lymphoma after 2 or more lines of systemic treatment [TA1139]</a>	Recommended	11/03/2026	TA		Non-ICB			This technology is commissioned by NHS England. Providers are NHS hospital trusts	NHS England
<a href="#">Nivolumab with chemotherapy for untreated unresectable or metastatic urothelial cancer (terminated appraisal) [TA1141]</a>	Terminated appraisal	17/03/2026	TA					N/A	Terminated appraisal
<a href="#">Ruxolitinib cream for treating non-segmental vitiligo in people 12 years and over [TA1140]</a>	Recommended	17/03/2026	TA	15/06/2026	ICB			This technology is commissioned by integrated care boards. Providers are NHS hospital trusts.	Red RAG proposed
<a href="#">Dupilumab for maintenance treatment of uncontrolled chronic obstructive pulmonary disease with raised blood eosinophils [TA1142]</a>	Recommended	26/03/2026	TA	24/06/2026	ICB			This technology is commissioned by integrated care boards. Providers are NHS hospital trusts.	Red RAG proposed
<a href="#">Fezolinetant for treating moderate to severe vasomotor symptoms associated with menopause [TA1143]</a>	Recommended	31/03/2026	TA	29/06/2026	ICB			This technology is commissioned by integrated care boards. Providers are primary care and secondary care providers.	In progress